FDA approves IND application for Ph 1 trial of KGX105 monotherapy in locally advanced or metastatic solid tumors
Dr. Weidong Jiang, Chief Executive Officer of KangaBio, commented: “The FDA’s clearance of KGX105, our second pipeline candidate, for clinical trials marks a pivotal moment in the company’s growth and reflects the increasing maturity of our prodrug platform technology. We look forward to thoroughly evaluating the safety and preliminary efficacy of KGX105 in this Phase 1 study, which will lay a solid foundation for its continued clinical development. The encouraging early clinical results from KGX101 have further validated our prodrug platform, offering valuable insights and confidence as we advance our pipeline. We extend our sincere gratitude to both existing and new investors for their continued trust and support. We are committed to accelerating the progress of our clinical programs and bringing new treatment hope to cancer patients around the world.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us